MedTrace Logo

Combining Donepezil With Perceptual Learning in Normal and Amblyopic Human The Effect of Donepezil on Perceptual Learning in Adult Amblyopia

NCT03109314 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-01-17

No results posted yet for this study

Summary

The research deals with amblyopia or lazy eye, a condition that affects about 3% of the population, and results in a variety of visual deficits. Recent work suggests that there is limited neural plasticity in the visual system of adults with amblyopia. This study is aimed at understanding and increasing this plasticity. In this study, the investigators aim to understand how the amblyopic brain learns and how this process is affected by a drug called donepezil, which is sometimes given as a treatment for Alzheimer's disease. The investigators hope that this study will help to identify the chemical components that help the brain to learn, as well as the mechanism of amblyopia. The investigators also plan to test the normal periphery, as control.

Conditions

  • Amblyopia

Interventions

DRUG

Donepezil

Donepezil will be administered to subjects three days before each training, and during training, to evaluate if donepezil improves the effectiveness of training.

BEHAVIORAL

Single-letter training

Subjects will undergo training to identify single letters (10,000 trials, or 10 blocks per session for 10 sessions).

BEHAVIORAL

Uncrowd training

Subjects will undergo training to identify letters closely flanked by other letters (10,000 trials, or 10 blocks per session for 10 sessions).

Sponsors & Collaborators

  • Dennis Levi

    lead OTHER

Principal Investigators

  • Dennis M Levi, OD, PhD · University of California, Berkeley

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-01
Primary Completion
2018-12-01
Completion
2018-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03109314 on ClinicalTrials.gov